VRTX Vertex Pharmaceuticals Incorporated

184.94
+3.82  (+2%)
Previous Close 181.12
Open 183.08
Price To Book 9.38
Market Cap 47,536,134,828
Shares 257,035,443
Volume 1,331,099
Short Ratio
Av. Daily Volume 1,223,634

NewsSee all news

  1. Top Research Reports: Amazon, Caterpillar, Vertex & More
  2. Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals
  3. Mergers & Acquisitions Take Center Stage in Biotech Industry
  4. Better Buy: Vertex Pharmaceuticals vs. Alexion Pharmaceuticals
  5. The 10 Largest-Cap Growth Stocks

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 positive data released November 27, 2018. 14% improvement in ppFEV1 cf placebo.
VX-659 in combination with tezacaftor and ivacaftor
Cystic fibrosis (CF) who have one F508del mutation and one minimal function mutation (F508del/Min)
Label expanded to now include all patients over 6 years old - June 21, 2019.
Tezacaftor / ivacaftor
Cystic fibrosis - Two Copies of the F508del Mutation
Phase 2 data released July 18, 2017. ppFEV1 of 12.0 percentage points.
VX-440 in combination with tezacaftor and ivacaftor
Cystic fibrosis who have one F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation
Approved December 29, 2014.
KALYDECO
Cystic fibrosis (CF) ages 6 and older who have the R117H mutation
Phase 2 primary endpoint met - January 25, 2017.
VX-150
Osteoarthritis
CRL issued February 5, 2016.
KALYDECO (ivacaftor)
Cystic fibrosis (CF) ages 2 and older who have one of 23 residual function mutations.
Approved July 2, 2015.
Lumacaftor and ivacaftor
Cystic fibrosis (CF) ages 12 and older who have two copies of the F508del mutation
Approved March 17, 2015.
KALYDECO (ivacaftor)
Children ages 2 to 5 with cystic fibrosis who have the G551D or one of the eight additional gating mutations
NDA filing due 1Q 2018.
ORKAMBI
Two Copies of the F508del Mutation - children ages 2 to 5
Phase 3 data released October 25, 2017 - primary endpoint not met.
Tezacaftor (VX-661) / ivacaftor
Cystic fibrosis - one copy of the F508del mutation and a second mutation that results in a gating mutation
Phase 3 trial terminated August 2016
VX-661
Cystic fibrosis - one copy of the F508del mutation and a second mutation that results in minimal CFTR Function
Approved September 28, 2016.
ORKAMBI
Cystic fibrosis (CF) ages 6-11 who have F508del mutation
Phase 2 data released July 18, 2017. ppFEV1 of 9.7 percentage points.
VX-152 in combination with tezacaftor and ivacaftor
Cystic fibrosis who have one F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation
Phase 2 data released December 18, 2018. Primary endpoint met.
VX-150
Neuropathic pain
Phase 3 positive data released November 27, 2018. 10% improvement in ppFEV1 cf placebo.
VX-659 in combination with tezacaftor and ivacaftor
Cystic Fibrosis Who Have Two Copies of the F508del Mutation
NDA filing announced July 22, 2019. Priority review requested.
VX-445 in combination with tezacaftor and ivacaftor
Cystic fibrosis (CF) who have one copy of the F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation
Phase 1/2 trial first patient enrolled - noted February 25, 2019.
CTX001
Sickle cell disease
Phase 1/2 initial data due late-2019.
CTX001
Beta-thalassemia
FDA Approval announced August 7, 2018.
Ivacaftor
Cystic fibrosis (CF) ages 2 to 5.
Approval announced August 15, 2018.
Lumacaftor and ivacaftor
Cystic fibrosis (CF) ages 1-2.
FDA Approval announced April 30, 2019.
Ivacaftor
Cystic Fibrosis (6-12 mths)
sNDA filing due late 2018.
Tezacaftor and ivacaftor
Cystic Fibrosis (Age 6-11)
Phase 2 monotherapy trial initiated 2Q 2019.
VX-561
Cystic fibrosis who have a gating mutation
Phase 2 combo trial initiated May 2019.
VX-561 and VX-121
Cystic Fibrosis
Phase 2 trial planned.
VX-814
alpha-1 antitrypsin (AAT) deficiency

Latest News

  1. Top Research Reports: Amazon, Caterpillar, Vertex & More
  2. Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals
  3. Mergers & Acquisitions Take Center Stage in Biotech Industry
  4. Better Buy: Vertex Pharmaceuticals vs. Alexion Pharmaceuticals
  5. The 10 Largest-Cap Growth Stocks
  6. Puma (PBYI) Q2 Earnings Miss, Nerlynx Sales Rise, Stock Up
  7. Perrigo (PRGO) Beats on Q2 Earnings and Sales, Stock Up
  8. Celldex (CLDX) Q2 Loss Narrower Than Expected, Revenues Miss
  9. Is Vertex (VRTX) a Great Growth Stock?
  10. 3 ‘Strong Buy’ Healthcare Stocks Insiders Are Buying Now
  11. Sarepta moves beyond rare disease, eyes multiple sclerosis gene therapy
  12. Edited Transcript of VRTX earnings conference call or presentation 31-Jul-19 8:30pm GMT
  13. Vertex Pharmaceuticals Inc (VRTX) EVPChief Commercial Officer Stuart A Arbuckle Sold $657,132 ...
  14. Vertex Has "Significant Financial Firepower"
  15. Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year?
  16. Will This Asteroid Heading Toward Vertex Pharmaceuticals Make Impact?
  17. Top Biotech Stocks for February 2019
  18. Vertex Pharmaceuticals Stock Soared on a Strong Earnings Report
  19. US Stocks Deep in the Red on Thursday
  20. Vertex Pharmaceuticals Raises Guidance, Shares Follow